Zacks Research Has Optimistic Outlook of ResMed Q3 Earnings

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research raised their Q3 2025 earnings per share estimates for shares of ResMed in a research report issued to clients and investors on Wednesday, February 19th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.33 for the quarter, up from their previous forecast of $2.30. The consensus estimate for ResMed’s current full-year earnings is $9.44 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.39 EPS, FY2025 earnings at $9.35 EPS, Q1 2026 earnings at $2.28 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.63 EPS, Q1 2027 earnings at $2.49 EPS, Q2 2027 earnings at $2.60 EPS and FY2027 earnings at $10.61 EPS.

Several other research analysts have also issued reports on RMD. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday, January 31st. Stifel Nicolaus began coverage on ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 target price on the stock. UBS Group upgraded ResMed from a “hold” rating to a “strong-buy” rating in a report on Friday, January 31st. JPMorgan Chase & Co. lifted their target price on ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Finally, Robert W. Baird lifted their target price on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, ResMed presently has an average rating of “Moderate Buy” and an average target price of $244.73.

ResMed Stock Down 0.7 %

NYSE:RMD opened at $232.89 on Friday. ResMed has a 12-month low of $170.56 and a 12-month high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $34.20 billion, a P/E ratio of 27.50, a P/E/G ratio of 1.55 and a beta of 0.70. The stock’s fifty day simple moving average is $237.57 and its 200-day simple moving average is $238.96.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.

Hedge Funds Weigh In On ResMed

Institutional investors have recently bought and sold shares of the business. Creative Planning boosted its holdings in shares of ResMed by 15.4% during the third quarter. Creative Planning now owns 28,021 shares of the medical equipment provider’s stock worth $6,840,000 after acquiring an additional 3,739 shares during the period. Blue Trust Inc. boosted its holdings in shares of ResMed by 359.4% during the third quarter. Blue Trust Inc. now owns 974 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 762 shares during the period. Signaturefd LLC boosted its holdings in shares of ResMed by 1.7% during the third quarter. Signaturefd LLC now owns 4,211 shares of the medical equipment provider’s stock worth $1,028,000 after acquiring an additional 72 shares during the period. Lecap Asset Management Ltd. bought a new stake in shares of ResMed during the third quarter worth approximately $366,000. Finally, Commerzbank Aktiengesellschaft FI bought a new stake in shares of ResMed during the third quarter worth approximately $226,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Activity at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the transaction, the director now owns 77,218 shares of the company’s stock, valued at $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the transaction, the chief executive officer now directly owns 455,472 shares in the company, valued at approximately $107,842,105.44. This trade represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,147 shares of company stock valued at $2,905,745. 0.71% of the stock is owned by insiders.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Thursday, February 13th. ResMed’s dividend payout ratio is currently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.